PHARMING HIGHLIGHTS RESEARCH INNOVATION AND NEW GROWTH ERA AT UBS CONFERENCE

Leiden, The Netherlands, September 25, 2006. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) presented today on its value creation and research innovation at the UBS Global Life Sciences Conference in New York.

The UBS conference is one of the largest healthcare meetings in the world attended by over 3000 individuals from healthcare/biotech companies, financial institutions, analysts and investors. The conference represents a major opportunity for licensing discussions and for establishing research collaborations.

"The presentation captures the value creation and research innovation achieved by Pharming over the last few years," said Dr. Francis J. Pinto, CEO of Pharming. "A remarkable turnaround has been completed and we are entering an exciting growth era with our Marketing Authorization Application for treatment of acute attacks of hereditary angioedema with Rhucin® recently accepted for review by EMEA, the upcoming finalization of the acquisition of DNage and our recent move to the new Beagle research headquarters."

The presentation entitled 'Pharming Group NV - A Case Study in Value Creation using Research Innovation' is available for review on the Pharming website, www.pharming.com .

Background on Pharming Group NV

Pharming Group NV is developing innovative protein products for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human lactoferrin for use in functional foods (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com .

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker (NL)     Sarah MacLeod  (UK)     Samir Singh (US)
Investor Voice          Financial Dynamics      Pharming Group NV
T:  31 (0)6 537 49959   T:  44 (0)20 7269 7148  T:  1 908  720 6224
T:  31 (0)71 524 7431   T:  44 (0)7747 602 739  T:  1 800  333 1476